Digital health platform monitors patients with machine learning

A UK-based technology company has created a new digital health platform that uses machine learning to help predict a user’s health conditions.

The Verum platform, created by UK-based firm Cambridge Consultants, is equipped with sensors integrated with wearables, a data collection application and a healthcare dashboard widget that helps physicians and nurses monitor patients remotely. The platform also uses machine-learning to help make predictions about the user’s current health condition.

“Within the consumer space, Verum can enable consumer brands to gain measured, quantitative insights into the use of products during trials,” the company said in a statement. “This could accelerate the product development process and provide new insights to spark innovation.”

The platform’s capabilities will first be tested on participants in clinical trials, with hopes it’ll be able to mitigate the effect patient stress has on trial outcomes. Developers hope the platform will be able to provide insight about stress triggers for patients and alert nurses and trial coordinators of the participant’s current condition.

The company believes other potential uses for the platform could include: diagnosing neurological conditions, rehabilitation and post market surveillance of drugs.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.